Rigel Pharmaceuticals Inc (RIGL)
Healthcare
Biotechnology
36.80 $
-3.3%
vs. previous close
Closing price · As of: 31. Jul 2026
Who owns Rigel Pharmaceuticals Inc (RIGL)? This page shows the largest institutions and funds, the ownership structure and the latest insider transactions. 86.1% of the shares are freely tradable; institutional investors hold 94.8%.
Ownership Structure
Institutional ownership
Share of the stock held by institutional investors (funds, banks, insurers) according to regulatory filings.
94.8%
Insiders
Share of the stock held by the executives, founders and major shareholders of the company itself.
3.3%
Float
Share of stock freely tradable on the market — not locked up in the hands of founders, insiders, or major shareholders.
86.1%
Short % of float
Shares sold short as a percentage of the freely tradable float — high values signal many bets on falling prices.
19.2%
Shares Outstanding
Total number of shares issued. Price times share count gives market cap.
19Mio.
Largest Shareholders
Institutions
| Name | Stake (%) | Shares | Change (%) | Date |
|---|---|---|---|---|
| BlackRock Inc | 9.56 | 1,768,907 | +6.3 | 03/31/2026 |
| Armistice Capital, LLC | 6.92 | 1,280,000 | +53.1 | 03/31/2026 |
| State Street Corp | 6.05 | 1,120,238 | +2.7 | 03/31/2026 |
| Vanguard Group Inc | 5.61 | 1,038,408 | -0.5 | 12/31/2025 |
| Vanguard Capital Management, LLC | 4.13 | 764,193 | +0.0 | 03/31/2026 |
| Acadian Asset Management LLC | 3.60 | 666,426 | +802.4 | 03/31/2026 |
| LSV Asset Management | 3.25 | 601,507 | +10.5 | 03/31/2026 |
| Marshall Wace Asset Management Ltd | 3.23 | 598,378 | -2.5 | 03/31/2026 |
Funds
| Name | Stake (%) | Shares | Change (%) | Date |
|---|---|---|---|---|
| State Street® SPDR® S&P® Biotech ETF | 4.24 | 784,304 | -0.6 | 05/31/2026 |
| Avantis US Small Cap Value ETF | 3.22 | 594,889 | +0.1 | 05/30/2026 |
Largest reported positions according to regulatory filings; stake as a percentage of shares outstanding, change versus the previous filing. Source: fundamentals data.
Data as of: July 31, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.